```html

Uterine Arteriovenous Malformation (UAVM) – A Comprehensive Guide

Overview

Uterine arteriovenous malformation (UAVM) is a rare vascular anomaly in which there is a direct, abnormal connection between the uterine arteries and veins, bypassing the normal capillary network. This creates a high‑flow channel that can lead to significant bleeding, most often during or after menstruation, pregnancy, or surgical procedures involving the uterus.

Although UAVMs can occur at any age, they are most frequently diagnosed in women of reproductive age (20–45 years). The true prevalence is difficult to determine because many cases are asymptomatic and go undetected; however, epidemiologic data from tertiary referral centers suggest an incidence of roughly 1–2 per 10,000 pregnancies and approximately 0.1–0.5 % of women undergoing hysterectomy for abnormal bleeding (Mayo Clinic, 2023; Radiology journal, 2022).

Symptoms

Symptoms vary widely, ranging from incidental findings on imaging to life‑threatening hemorrhage. Common presentations include:

• Heavy menstrual bleeding (menorrhagia): Bleeding that soaks through a pad or tampon every hour, lasts longer than 7 days, or requires changing pads every hour.
• Post‑coital bleeding: Spotting or heavy bleeding after intercourse.
• Painless vaginal bleeding: May occur between periods (metrorrhagia) or after childbirth.
• Acute postpartum hemorrhage: Severe bleeding within 24 hours of delivery.
• Bleeding after uterine instrumentation: Such as dilation and curettage (D&C), hysteroscopy, or endometrial biopsy.
• Pelvic pain or pressure: Usually mild; severe pain is uncommon unless there is a large associated hematoma.
• Iron‑deficiency anemia: Resulting from chronic blood loss – symptoms may include fatigue, dizziness, or shortness of breath.
• Incidental finding on imaging: UAVM can be discovered during ultrasound or MRI performed for unrelated reasons.

Causes and Risk Factors

What causes UAVM?

UAVMs are classified as either congenital or acquired. The majority of reported cases are acquired.

• Acquired UAVM usually follows an event that disrupts normal uterine vasculature:
  • Uterine surgery (e.g., cesarean section, myomectomy, hysterectomy, D&C)
  • Pelvic trauma
  • Severe uterine infection or inflammation (e.g., endometritis)
  • Placental abnormalities such as placenta previa or accreta
• Congenital UAVM results from developmental errors during embryogenesis, leading to a persistent fistulous connection between arteries and veins. These are extremely rare and often identified in childhood or adolescence.

Who is at higher risk?

• Women who have undergone recent uterine surgery or instrumentation (within the past 6 months).
• History of multiple pregnancy terminations or curettage procedures.
• Prior cesarean delivery or complicated childbirth.
• Patients with chronic pelvic inflammatory disease (PID).
• Women of reproductive age; post‑menopausal onset is uncommon but has been reported after hormonal therapy.

Diagnosis

Because UAVM can mimic other causes of abnormal uterine bleeding (e.g., fibroids, polyps, malignancy), a systematic diagnostic approach is essential.

1. Clinical evaluation

• Detailed menstrual and reproductive history.
• Physical exam focusing on abdominal tenderness, uterine size, and any visible trauma.

2. Imaging studies

• Transvaginal Doppler ultrasound – First‑line test. UAVM appears as a heterogeneous, hypoechoic area with multiple serpentine channels and high‑velocity, low‑resistance flow (peak systolic velocity > 30 cm/s). Color Doppler “aliasing” pattern is characteristic.
• Pelvic MRI with contrast – Provides superior soft‑tissue detail, helps differentiate UAVM from fibroids or malignancy, and assesses the extent of vascular involvement.
• CT angiography (CTA) – Useful when planning endovascular treatment; delineates feeding arteries and draining veins.
• Selective pelvic angiography – Gold standard. Direct catheter‑based imaging confirms the diagnosis and allows simultaneous therapeutic embolization.

3. Laboratory tests

• Complete blood count (CBC) – Assess anemia.
• Serum ferritin and iron studies – Evaluate chronic blood loss.
• Pregnancy test – Important before any invasive procedure.

4. Histopathology (rare)

In cases where hysterectomy is performed, surgical specimens may be examined to confirm the abnormal vascular channels.

Treatment Options

Management depends on symptom severity, desire for future fertility, and the size/location of the malformation.

1. Conservative / Observation

• Asymptomatic patients or those with minimal bleeding may be monitored with serial ultrasounds every 3–6 months.
• Iron supplementation for mild anemia.

2. Medical therapy

There is no medication that directly eliminates an arteriovenous malformation, but certain drugs can help control bleeding:

• Tranexamic acid – Antifibrinolytic that reduces menstrual blood loss (up to 40 % in clinical trials).
• Hormonal therapy (combined oral contraceptives, progestin‑only pills, or levonorgestrel IUS) – May decrease bleeding by stabilizing the endometrium, but does not resolve the vascular lesion.
• GnRH agonists – Temporarily shrink the uterus and can reduce flow; used short‑term (<6 months) because of side‑effects.

3. Interventional radiology – First‑line definitive therapy

• Uterine artery embolization (UAE) – Catheter‑based delivery of particles (e.g., polyvinyl alcohol, trisacryl gelatin) to occlude feeding arteries. Success rates 85–95 % for symptom control and preservation of fertility (Cleveland Clinic, 2022).
• Selective arterial embolization – Targets only the vessels supplying the AVM, sparing normal uterine tissue.
• Complications are rare but may include transient pelvic pain, post‑embolization syndrome (fever, malaise), or non‑target embolization.

4. Surgical options

• Hysteroscopic resection – For small, focal lesions accessible via the cervical canal. Requires skilled surgeon; risk of recurrence.
• Laparoscopic or open uterine artery ligation – Reduces blood flow but is less effective than UAE.
• Hysterectomy – Definitive cure; recommended for women who have completed childbearing, have massive refractory bleeding, or when less‑invasive therapies fail.

5. Lifestyle & supportive care

• Iron‑rich diet (red meat, beans, fortified cereals) and supplementation as needed.
• Regular follow‑up with a gynecologist experienced in vascular uterine disorders.
• Avoidance of unnecessary uterine instrumentation when possible.

Living with Uterine Arteriovenous Malformation

Daily Management Tips

• Track bleeding – Use a menstrual diary or mobile app to record flow intensity, duration, and any clotting. This helps guide follow‑up visits.
• Maintain adequate iron levels – Take prescribed iron supplements with vitamin C to enhance absorption; schedule CBC checks every 3 months.
• Plan pregnancies carefully – Women desiring pregnancy should discuss timing of embolization (usually 6–12 months before conception) with their interventional radiologist and obstetrician.
• Stay active – Light to moderate exercise improves circulation and overall health, but avoid high‑impact contact sports that might cause pelvic trauma.
• Know your medications – Inform any new health‑care provider about your UAVM; certain anticoagulants or NSAIDs can worsen bleeding.
• Emotional support – Chronic bleeding can be stressful. Consider counseling, support groups, or online forums for women with rare uterine conditions.

Prevention

Because many UAVMs are acquired after uterine injury, preventive strategies focus on minimizing trauma to the uterus:

• Use gentle techniques during D&C or hysteroscopy; limit the number of repeat procedures.
• Treat pelvic infections promptly to avoid chronic inflammation.
• Consider medical termination of pregnancy (e.g., medication‑based) when appropriate, as surgical curettage carries higher risk of vascular injury.
• Optimize obstetric care – Skilled delivery teams reduce the need for emergency cesarean sections or postpartum curettage.
• Regular gynecologic exams – Early detection of abnormal bleeding allows timely imaging before a large AVM develops.

Complications

If left untreated, UAVM can lead to serious health problems:

• Severe hemorrhage – Acute blood loss may require transfusion, intensive care, or emergency hysterectomy.
• Iron‑deficiency anemia – Chronic fatigue, decreased exercise tolerance, and impaired cognitive function.
• Infertility or recurrent pregnancy loss – Massive vascular flow can interfere with implantation or cause placental abnormalities.
• Hemodynamic instability – In rare high‑flow lesions, the shunt can cause a drop in systemic vascular resistance, leading to low blood pressure and tachycardia.
• Psychological impact – Ongoing bleeding can cause anxiety, depression, and reduced quality of life.

When to Seek Emergency Care

Key Take‑aways

• Uterine arteriovenous malformation is a rare but potentially serious cause of abnormal uterine bleeding.
• Most cases are acquired after surgery, trauma, or infection; congenital forms are extremely uncommon.
• Transvaginal Doppler ultrasound and selective angiography are the cornerstone diagnostic tools.
• Uterine artery embolization offers high success rates while preserving fertility; hysterectomy remains a definitive option for refractory cases.
• Regular follow‑up, iron management, and avoidance of unnecessary uterine procedures are essential for long‑term health.

For personalized guidance, always discuss symptoms and treatment options with a qualified gynecologist or interventional radiologist. Early diagnosis and appropriate intervention dramatically improve outcomes and quality of life.

```